Asset
REMESTEMCEL-L
Mesoblast Limited American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02336230 | phase3 | completed | 2015-06-04 | 2018-04-09 | Mesoblast, Inc. | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) |
| NCT00366145 | phase3 | completed | 2006-08-17 | 2008-12-26 | Mesoblast, Inc. | Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD) |
| NCT00562497 | phase3 | completed | 2008-01-31 | 2009-07-14 | Mesoblast, Inc. | Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) |
| NCT00482092 | phase3 | completed | 2007-09-17 | 2014-09-15 | Mesoblast, Inc. | Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease |
| NCT01233960 | phase3 | completed | 2010-11-29 | 2014-09-15 | Mesoblast, Inc. | Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease |
FDA applications (0)
This company has no applications containing this asset.